WST

WST

USD

West Pharmaceutical Services Inc. Common Stock

$286.940+8.560 (3.075%)

Prix en Temps Réel

Healthcare
Medical Instruments & Supplies
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$278.380

Haut

$287.875

Bas

$277.195

Volume

0.41M

Fondamentaux de l'Entreprise

Capitalisation Boursière

20.6B

Industrie

Medical Instruments & Supplies

Pays

United States

Statistiques de Trading

Volume Moyen

0.64M

Bourse

NYQ

Devise

USD

Intervalle sur 52 Semaines

Bas $187.43Actuel $286.940Haut $348.9

Actualités Connexes

Analyst Upgrades

TD Cowen Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $350

TD Cowen analyst Brendan Smith initiates coverage on West Pharmaceutical Servs with a Buy rating and announces Price Target of $350.

Voir plus
TD Cowen Initiates Coverage On West Pharmaceutical Servs with Buy Rating, Announces Price Target of $350
Analyst Upgrades

Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $325

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs with a Equal-Weight and raises the price target from $275 to $325.

Voir plus
Barclays Maintains Equal-Weight on West Pharmaceutical Servs, Raises Price Target to $325
PR Newswire

West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the...

Voir plus
West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
Analyst Upgrades

UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $355

UBS analyst John Sourbeer maintains West Pharmaceutical Servs with a Buy and raises the price target from $320 to $355.

Voir plus
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $355
Analyst Upgrades

Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $350

Keybanc analyst Paul Knight maintains West Pharmaceutical Servs with a Overweight and raises the price target from $325 to $350.

Voir plus
Keybanc Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $350
PR Newswire

West to Participate in Upcoming Investor Conferences

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it...

Analyst Upgrades

Evercore ISI Group Maintains Outperform on West Pharmaceutical Servs, Raises Price Target to $390

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs with a Outperform and raises the price target from $350 to $390.

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.